首页 | 官方网站   微博 | 高级检索  
     

趋化因子CXCL5在前列腺癌组织表达的研究
引用本文:王伟群,孟德欣,齐亚灵,齐淑芳,梁立春,李晶,贾秀月.趋化因子CXCL5在前列腺癌组织表达的研究[J].生殖与避孕,2012,32(7):449-451,448.
作者姓名:王伟群  孟德欣  齐亚灵  齐淑芳  梁立春  李晶  贾秀月
作者单位:佳木斯大学基础医学院,佳木斯,154007
基金项目:黑龙江省教育厅科学技术研究项目
摘    要:目的:研究趋化因子CXCL5在前列腺癌组织样本的表达。方法:免疫组织化学方法检测CXCL5在前列腺癌样本与良性前列腺增生样本的表达差异。结果:CXCL5在前列腺癌样本和良性前列腺增生样本的阳性表达率分别为78.3%(18/23)和47.4%(9/19),两者差异有统计学意义(P<0.05)。结论:CXCL5与其上游分子NDRG3可能共同参与前列腺癌的发展。

关 键 词:前列腺癌  CXCL5  免疫组织化学

Expression of Chemotatic Factor CXCL5 in Prostatic Carcinoma Tissue
Wei-qun WANG , De-xin MENG , Ya-ling QI , Shu-fang QI , Li-chun LIANG , Jing LI , Xiu-yue JIA.Expression of Chemotatic Factor CXCL5 in Prostatic Carcinoma Tissue[J].Reproduction and Contraception,2012,32(7):449-451,448.
Authors:Wei-qun WANG  De-xin MENG  Ya-ling QI  Shu-fang QI  Li-chun LIANG  Jing LI  Xiu-yue JIA
Affiliation:1.The Basic Medical College of Jiamusi University,Jiamusi,154007)
Abstract:Objective: To study the expression of chemotatic factor CXCL5 in prostatic carcinoma tissular samples.Method: The expression difference of CXCL5 in prostatic carcinoma samples and benign prostatic hyperplasia(BPH) samples were measured by immunohistochemical assay.Results: The possitive rates of CXCL5 expression were 78.3%(18/23) in the prostate cancer specimens,and 47.4%(9/19) in the BPH specimens.There was a significant difference between the two groups(P<0.05).Conclusion: CXCL5 and its upper stream molecule NDRG3 may participate in development of prostatic carcinoma.
Keywords:prostatic carcinoma  CXCL5  immunohistochemical
本文献已被 CNKI 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号